Verge Genomics, a biotech company that has created an industry leading all-in-human, artificial-intelligence-powered drug discovery and development platform focused on therapies for serious genetic diseases, today announced that data from preclinical studies using its novel PIKfyve inhibitor VRG101 showed broad spectrum of antiviral activity. The results will be presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) online meeting being held July 9-12, 2021.
“There remains an urgent need for oral antiviral treatments for SARS-CoV-2 and its variants,” said Alice Zhang, CEO and Co-Founder of Verge Genomics. “SARS-CoV-2 and other novel coronaviruses are expected to be with us for many years and finding antivirals to combat them is critical to improving public health now and in the future. Based on the results of this study, we believe advancing the development of VRG101 as a prophylacstic and preemptive therapy in SARS-CoV-2 patients, and future novel human coronaviruses, is a compelling opportunity.”
Details of Poster Presentation:
TITLE: Novel PIKfyve Inhibitor has Broad Spectrum Antiviral Activity in Preclinical Experiments
ABSTRACT: 04776
PRESENTATION: Monday, July 12, 2021, 16:00-17:00 CEST
FIRESIDE SESSION: Monday, July 12, 2021, 18:15-19:15 CEST
PRESENTER: Michelle I. Mighdoll
AWARDED: Best Rated Poster Award, based on rating by peer reviewers (approximately one percent of submitted abstracts)
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.